Dtsch Med Wochenschr 2010; 135(38): 1871
DOI: 10.1055/s-0030-1263330
Pro & Contra | Commentary
Hämatologie, Infektiologie
© Georg Thieme Verlag KG Stuttgart · New York

Pilzprophylaxe bei hämatologischen Patienten: contra

Prophylaxis of fungal infections in haematological patients: contraS. Schwartz1
  • 1Medizinische Klinik III, Charité – Universitätsmedizin Berlin, Campus Benjamin Franklin
Further Information

Publication History

Publication Date:
14 September 2010 (online)

Literatur

  • 1 Cornely O A. et al . Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.  N Engl J Med. 2007;  356 348-359
  • 2 Glasmacher A. et al . Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients.  J Clin Oncol. 2003;  21 4615-4626
  • 3 Marr K A. et al . Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants.  Blood. 2004;  103 1527-1533
  • 4 Marr K A, Laverdiere M, Gugel A, Leisenring W. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay.  Clin Infect Dis. 2005;  40 1762-1769
  • 5 Marr K A. et al . Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients.  Blood. 2000;  96 2055-2061
  • 6 Schaffner A, Frick P G. The effect of ketoconazole on amphotericin B in a model of disseminated aspergillosis.  J Infect Dis. 1985;  151 902-910
  • 7 Verweij P E, Snelders E, Kema G H, Mellado E, Melchers W J. Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use?.  Lancet Infect Dis. 2009;  9 789-795

PD Dr. Stefan Schwartz

Medizinische Klinik III
Charité – Universitätsmedizin Berlin
Campus Benjamin Franklin

Hindenburgdamm 30

12200 Berlin

Phone: 030/8445-4022

Fax: 030/8445-4468

Email: stefan.schwartz@charite.de

    >